Bayer takes on full rights to Vitrakvi and BAY 2731954

15 February 2019
bayer-cross-big

German pharma and crop sciences major Bayer (BAYN: DE) has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, for Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195).

Both compounds are being developed globally for the treatment of adult and pediatric patients with advanced solid tumors harboring NTRK gene fusions. The option was triggered by the$8 billion acquisition of Loxo Oncology by Eli Lilly (NYSE: LLY), which became effective today. As a result of this exercise, the joint co-promotion agreement in the USA between Bayer and Loxo Oncology is being converted to full commercialization in the USA by Bayer. Vitrakvi gained US Drug Administration approval in November last years

Bayer’s original deal with Loxo was agreed in November 2017, ways before Lilly announced its intention of acquiring the company, and could have earned Loxo as much as $1.55 billion, of which $400 million was paid up front. Today’s news saw Bayer’s shares gain 4.1% to 68.24 euros by close of trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology